- NCIt
- C95884
Loading cancer entity…
Loading cancer entity…
Clinical trials
5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02595424 | Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 67 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 |
| NCT06663852 | ML Decision Model for G-NEC Adjuvant Therapy(G-NEC) | completed | — | 1,505 | Chang-Ming Huang, Prof.OTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06102746 | Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma | unknown | — | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05671393 | the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma | completed | — | 801 | Fujian Medical UniversityOTHER | 1 | Jan 4, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2026source: clinicaltrials